Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 10 of 19

Publication Record

Connections

Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1.
Werfel TA, Elion DL, Rahman B, Hicks DJ, Sanchez V, Gonzales-Ericsson PI, Nixon MJ, James JL, Balko JM, Scherle PA, Koblish HK, Cook RS
(2019) Cancer Res 79: 171-182
MeSH Terms: Animals, Antineoplastic Agents, Apoptosis, Female, Indoleamine-Pyrrole 2,3,-Dioxygenase, Inflammation, Lapatinib, Lung Neoplasms, Macrophages, Mammary Neoplasms, Experimental, Mice, Necrosis, Phagocytosis, Receptor, ErbB-2, T-Lymphocytes, Regulatory, Tumor Microenvironment, c-Mer Tyrosine Kinase
Added April 15, 2019
0 Communities
1 Members
0 Resources
17 MeSH Terms
Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival.
Werfel TA, Wang S, Jackson MA, Kavanaugh TE, Joly MM, Lee LH, Hicks DJ, Sanchez V, Ericsson PG, Kilchrist KV, Dimobi SC, Sarett SM, Brantley-Sieders DM, Cook RS, Duvall CL
(2018) Cancer Res 78: 1845-1858
MeSH Terms: Animals, Antineoplastic Agents, Cell Proliferation, Cell Survival, Disease Models, Animal, Female, Humans, Lapatinib, Mechanistic Target of Rapamycin Complex 2, Mice, Mice, Inbred BALB C, Mice, Nude, Nanoparticles, Protein Kinase Inhibitors, RNA, Small Interfering, Rapamycin-Insensitive Companion of mTOR Protein, Receptor, ErbB-2, Triple Negative Breast Neoplasms, Xenograft Model Antitumor Assays
Added March 14, 2018
0 Communities
2 Members
0 Resources
19 MeSH Terms
Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
Canfield K, Li J, Wilkins OM, Morrison MM, Ung M, Wells W, Williams CR, Liby KT, Vullhorst D, Buonanno A, Hu H, Schiff R, Cook RS, Kurokawa M
(2015) Cell Cycle 14: 648-55
MeSH Terms: Animals, Breast Neoplasms, Cell Line, Tumor, Drug Resistance, Neoplasm, Female, Gene Expression Regulation, Neoplastic, Gene Knockdown Techniques, Lapatinib, Mice, Quinazolines, Receptor, ErbB-2, Receptor, ErbB-4, Trastuzumab
Added February 12, 2015
1 Communities
1 Members
0 Resources
13 MeSH Terms
Evaluating HER2 amplification status and acquired drug resistance in breast cancer cells using Raman spectroscopy.
Bi X, Rexer B, Arteaga CL, Guo M, Mahadevan-Jansen A
(2014) J Biomed Opt 19: 025001
MeSH Terms: Breast Neoplasms, Cell Line, Tumor, Drug Resistance, Neoplasm, Female, Humans, Lapatinib, Quinazolines, Receptor, ErbB-2, Spectrum Analysis, Raman
Added March 7, 2014
0 Communities
3 Members
0 Resources
9 MeSH Terms
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
Rexer BN, Chanthaphaychith S, Dahlman K, Arteaga CL
(2014) Breast Cancer Res 16: R9
MeSH Terms: Aminopyridines, Animals, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Biomarkers, Tumor, Breast Neoplasms, Cell Line, Tumor, Cell Proliferation, Class I Phosphatidylinositol 3-Kinases, Drug Resistance, Neoplasm, Female, Humans, Lapatinib, Mice, Mice, Nude, Morpholines, Mutation, Phosphatidylinositol 3-Kinases, Phosphoinositide-3 Kinase Inhibitors, Protein Kinase Inhibitors, Quinazolines, Receptor, ErbB-2, Trastuzumab, Xenograft Model Antitumor Assays
Added March 10, 2014
0 Communities
3 Members
0 Resources
24 MeSH Terms
Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers.
Garrett JT, Sutton CR, Kurupi R, Bialucha CU, Ettenberg SA, Collins SD, Sheng Q, Wallweber J, Defazio-Eli L, Arteaga CL
(2013) Cancer Res 73: 6013-23
MeSH Terms: Animals, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Breast Neoplasms, Cell Proliferation, Class I Phosphatidylinositol 3-Kinases, Female, Humans, Immunoblotting, Immunoprecipitation, Lapatinib, Mice, Phosphorylation, Protein Multimerization, Proto-Oncogene Proteins c-akt, Quinazolines, Receptor, ErbB-2, Receptor, ErbB-3, Signal Transduction, Survival Rate, Trastuzumab, Tumor Cells, Cultured, Xenograft Model Antitumor Assays
Added September 3, 2013
0 Communities
2 Members
0 Resources
23 MeSH Terms
Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, Sánchez V, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL
(2013) Cancer Res 73: 4075-85
MeSH Terms: Animals, Antineoplastic Agents, Cell Line, Tumor, Class I Phosphatidylinositol 3-Kinases, Female, Gene Expression, Humans, Hyperplasia, Lapatinib, Mammary Glands, Animal, Mammary Neoplasms, Experimental, Mice, Mice, Nude, Mice, Transgenic, Mutation, Missense, Neoplasm Transplantation, Phosphatidylinositol 3-Kinases, Phosphoinositide-3 Kinase Inhibitors, Protein Binding, Quinazolines, Receptor, ErbB-2, Receptor, ErbB-3, Signal Transduction, Transcriptome, Tumor Burden
Added November 12, 2013
2 Communities
6 Members
0 Resources
25 MeSH Terms
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Rimawi MF, Mayer IA, Forero A, Nanda R, Goetz MP, Rodriguez AA, Pavlick AC, Wang T, Hilsenbeck SG, Gutierrez C, Schiff R, Osborne CK, Chang JC
(2013) J Clin Oncol 31: 1726-31
MeSH Terms: Adult, Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Hormonal, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Drug Administration Schedule, Female, Humans, Lapatinib, Letrozole, Lymphatic Metastasis, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Nitriles, Quinazolines, Receptor, ErbB-2, Receptors, Estrogen, Trastuzumab, Treatment Outcome, Triazoles, Up-Regulation
Added March 7, 2014
0 Communities
1 Members
0 Resources
23 MeSH Terms
Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.
Garrett JT, Sutton CR, Kuba MG, Cook RS, Arteaga CL
(2013) Clin Cancer Res 19: 610-9
MeSH Terms: Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Breast Neoplasms, Cell Line, Tumor, Female, Gene Expression Regulation, Neoplastic, Humans, Lapatinib, Phosphorylation, Protein Kinase Inhibitors, Quinazolines, Receptor, ErbB-2, Receptor, ErbB-3, Trastuzumab, Tumor Burden, Xenograft Model Antitumor Assays
Added September 3, 2013
1 Communities
3 Members
0 Resources
17 MeSH Terms
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J
(2012) Nature 487: 505-9
MeSH Terms: Antineoplastic Agents, Breast Neoplasms, Cell Line, Tumor, Cell Survival, Drug Resistance, Neoplasm, Female, Hepatocyte Growth Factor, Humans, Indoles, Lapatinib, Ligands, Melanoma, Mitogen-Activated Protein Kinases, Phosphatidylinositol 3-Kinases, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Quinazolines, Receptor Protein-Tyrosine Kinases, Receptor, ErbB-2, Signal Transduction, Sulfonamides, Vemurafenib
Added March 20, 2014
0 Communities
1 Members
0 Resources
22 MeSH Terms